26 December 2022 in Pediatric Hematology/Oncology and Immunopathology
Risk-adapted therapy is the standard of care for hepatoblastoma (HB). The aim of this study was to analyze the effectiveness of cisplatin monotherapy in patients with standard-risk HB. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. For the period 02.2012–12.2019 (95 months) 60 patients with standard-risk HB aged 0–8 years were treated within the framework of the cooperation of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation and B.V. Petrovsky Russian Scientific Center of Surgery. The SIOPEL criteria were used for stratification into risk groups. Throughout the study period, standard-risk patients received therapy per SIOPEL-3 SR protocol, including cisplatin monotherapy. Survival was assessed by the Kaplan–Meier method. For the purposes of this study, overall survival (OS), event-free survival (EFS), where any modification of chemotherapy regimen towards its escalation were considered as an additional event, and progression-free survival (PFS) were calculated. The survival analysis was carried out on 15.01.2021; 54/60 (90%) patients were treated with cisplatin monotherapy and included in the final analysis. Median age at diagnosis was 11.3 (range 0.0–87.7) months. Male:female ratio – 0.86:1. Distribution by PRETEXT stages: I – 14 (25.9%), II – 30 (55.6%), III – 10 (18.5%) patients. The median alphafetoprotein level at the time of diagnosis was 162 979 (range 129–2 000 000) ng/ml. Modification of therapy without confirmed relapse/progression was required in 3/54 patients. Median follow-up was 47.1 (range 2–99) months. Among 54 patients 52 (96.3%) are alive, 2 (3.7%) patients died (1/2 – complications of surgical treatment). Relapses/progressions were noted in 4/54 (7.4%) patients, one of whom died due to disease progression. The three-year OS was 98.1% (95% confidence interval (CI) 94.6–100), EFS – 85.1% (95% CI 75.5–94.6), PFS – 90.5% (95% CI 82.5–98.4). Our data are consistent with the original studies of the SIOPEL group and convincingly confirm the effectiveness of cisplatin monotherapy in patients with HB of the standard risk group in the Russian Federation. Currently this regimen is incorporated into the national clinical guidelines of HB therapy and considered as a standard of care.
13 August 2018 in Pediatria. Journal named after G.N. Speransky
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
+8
Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.
18 March 2020 in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
Aim. To analyze the short-term outcomes of сentral segments liver resection in children, according to the initial experience.Мethods. The data of patients with different centrally located liver neoplasms were analyzed. This retrospective study included three patients with hepatoblastoma, one observation of mesenchymal hamartoma of the liver and one patient with hepatocellular carcinoma. Different types of central liver resections were carried out in these patients between March and October 2018. The technical aspects and the short-term results are described.Results. Median age of patients was 78 months (9 months – 12 years). Patients underwent: segmentectomy 4b, bisegmentectomy 4b, 5, threesegmentectomy 4, 5, 6, mesohepatectomy (anatomical segmentectomy 4, 5, 8) with biliary reconstruction for posterior liver segments, mesohepatectomy with anatomical segmentectomy 6 and atypical S2, 3 resection. Dindo–Clavien grade IIIa postoperative complication developed in one patient. Vascular complications and posthepatectomy liver failure were absent. The hospital stay ranged between 9 to 14 days. The median follow-up period came to 8 months (7–14 months). The overall and event free survival at the time of writing is 100%.Conclusion. Resections of central liver segments in children are feasible and should be carried out in experiences in liver surgery centers.
30 June 2023 in Oncologia i Radiologia Kazakhstana
Relevance: Oncological diseases remain the main cause of death in children, increasing the need for intensive care. Hospitalized children suffering from oncological diseases are at high risk for sudden deterioration of their condition, both for the underlying disease and due to infectious complications and the toxic effects of medications. This review highlights information on the Pediatric Early Warning Signs (PEWS) system in oncological patients to detect clinical deterioration promptly. The study aimed to analyze international literature on the use of pediatric early warning signs (PEWS) for clinical deterioration in pediatric oncology. Methods: Current literature on using the PEWS of clinical deterioration in pediatric oncology was studied. Results: The published data show the important role of using the PEWS system in cancer patients for early detection of deterioration of the condition with subsequent provision of emergency medical care. Conclusion: The analysis of international experience has shown that using the PEWS system in children with oncological diseases is an effective method of early recognition of signs of clinical deterioration, which, in turn, allows the timely initiation of complex intensive therapy.
29 June 2023 in Oncologia i Radiologia Kazakhstana
Relevance: Oncological diseases remain the main cause of death in children, increasing the need for intensive care. Hospitalized children suffering from oncological diseases are at high risk for sudden deterioration of their condition, both for the underlying disease and due to infectious complications and the toxic effects of medications. This review highlights information on the Pediatric Early Warning Signs (PEWS) system in oncological patients to detect clinical deterioration promptly. The study aimed to analyze international literature on the use of pediatric early warning signs (PEWS) for clinical deterioration in pediatric oncology. Methods: Current literature on using the PEWS of clinical deterioration in pediatric oncology was studied. Results: The published data show the important role of using the PEWS system in cancer patients for early detection of deterioration of the condition with subsequent provision of emergency medical care. Conclusion: The analysis of international experience has shown that using the PEWS system in children with oncological diseases is an effective method of early recognition of signs of clinical deterioration, which, in turn, allows the timely initiation of complex intensive therapy.
8 September 2020 in Pediatric Hematology/Oncology and Immunopathology
The organization of acute massive blood loss therapy in pediatric surgical requires an interdisciplinary approach in each medical center, depending on their profile. In our center, a protocol of acute massive blood loss therapy in pediatric surgical oncology has been developed and implemented. Systematic training of personnel and the development of team skills in the simulation class of the center became the basis for its implementation. In addition, the earlier initiation of therapy (with blood loss of more than 1 ml/kg/min) and actions aimed at reducing the time of critical hypotension became important conditions of the protocol. The acquired coagulopathy therapy and the prevention of massive transfusion syndrome are carried out only after the normalization of systemic hemodynamics. We present our experience of using this protocol in a 3-year-old child with acute massive blood loss more than 400% of the circulating blood volume during surgical removal of сhoriocarcinoma. The presented clinical case demonstrates not only the dramatic nature of the course of the disease, but also the good results of the organization and coordination of the joint work of all the center’s specialists. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Parents gave their consent to use information about the child, including fotos, in the article.